We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Intrexon (XON) This Earnings Season?
Read MoreHide Full Article
Intrexon Corporation is expected to report second-quarter 2018 results on Aug 8, after the market closes.
In the last reported quarter, the company delivered a positive earnings surprise of 29.17%. Intrexon has an impressive surprise history. Of the trailing four quarters, the company surpassed estimates in all, with an average surprise beat of 26.81%.
Intrexon’s shares have returned 21.6% year to date, outperforming the industry’s growth of 13.1%.
Factors to Consider
Intrexon’s business model helps it commercialize technologies through exclusive channel collaborations (“ECC”), licensing agreements and joint ventures with collaborators that have market and product development expertise as well as sales and marketing capabilities. This facilitates the company to bring new and improved products and processes in the market. These agreements help Intrexon generate funds in the form of technology access fees and milestones along with other payments.
Intrexon is collaborating with various companies for developing several candidates. The company teamed up with Fibrocell Science, Inc. and completed enrollment in a phase I/II study on FCX-007 for recessive dystrophic epidermolysis bullosa. In January 2018, Fibrocell received an approval from the FDA to initiate enrollment of pediatric patients in the phase II portion of the phase I/II study of FCX-007.
Also, the second gene therapy candidate, FCX-013, is being developed by Fibrocell for the treatment of linear scleroderma.
Another collaborator, Oragenics, is developing AG013 for the prevention and treatment of oral mucositis in a phase II study. Oragenics utilizes Intrexon’s ActoBiotics platform.
Intrexon’s expanding portfolio of technologies has enabled the company develop a robust pipeline. The company’s efforts to growth by acquisitions and ECCs are encouraging. Therefore, we expect investors’ focus to remain on the company’s performance along with other developmental updates during the quarterly call.
What Our Model Indicates
Our proven model does not show an earnings beat for Intrexon this quarter. This is because a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to surpass estimates. That is not the case here, as you will see below.
Earnings ESP: Intrexon has an Earnings ESP of -29.03% as the Most Accurate Estimate is pegged at a loss of 30 cents and the Zacks Consensus Estimate is pegged at a loss of 23 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Intrexon has a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Endo International Plc. has an Earnings ESP of +1.37% and currently carries a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 8.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
What's in Store for Intrexon (XON) This Earnings Season?
Intrexon Corporation is expected to report second-quarter 2018 results on Aug 8, after the market closes.
In the last reported quarter, the company delivered a positive earnings surprise of 29.17%. Intrexon has an impressive surprise history. Of the trailing four quarters, the company surpassed estimates in all, with an average surprise beat of 26.81%.
Intrexon’s shares have returned 21.6% year to date, outperforming the industry’s growth of 13.1%.
Factors to Consider
Intrexon’s business model helps it commercialize technologies through exclusive channel collaborations (“ECC”), licensing agreements and joint ventures with collaborators that have market and product development expertise as well as sales and marketing capabilities. This facilitates the company to bring new and improved products and processes in the market. These agreements help Intrexon generate funds in the form of technology access fees and milestones along with other payments.
Intrexon is collaborating with various companies for developing several candidates. The company teamed up with Fibrocell Science, Inc. and completed enrollment in a phase I/II study on FCX-007 for recessive dystrophic epidermolysis bullosa. In January 2018, Fibrocell received an approval from the FDA to initiate enrollment of pediatric patients in the phase II portion of the phase I/II study of FCX-007.
Also, the second gene therapy candidate, FCX-013, is being developed by Fibrocell for the treatment of linear scleroderma.
Another collaborator, Oragenics, is developing AG013 for the prevention and treatment of oral mucositis in a phase II study. Oragenics utilizes Intrexon’s ActoBiotics platform.
Intrexon’s expanding portfolio of technologies has enabled the company develop a robust pipeline. The company’s efforts to growth by acquisitions and ECCs are encouraging. Therefore, we expect investors’ focus to remain on the company’s performance along with other developmental updates during the quarterly call.
What Our Model Indicates
Our proven model does not show an earnings beat for Intrexon this quarter. This is because a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to surpass estimates. That is not the case here, as you will see below.
Earnings ESP: Intrexon has an Earnings ESP of -29.03% as the Most Accurate Estimate is pegged at a loss of 30 cents and the Zacks Consensus Estimate is pegged at a loss of 23 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Intrexon has a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Intrexon Corporation Price and EPS Surprise
Intrexon Corporation Price and EPS Surprise | Intrexon Corporation Quote
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) has an Earnings ESP of +42.86% and currently carries a Zacks Rank #2. The company is scheduled to release second-quarter report on Aug 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Endo International Plc. has an Earnings ESP of +1.37% and currently carries a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 8.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>